Mayne Pharma Group |
High $4.46 |
Low $4.23 |
Trades 1,020 |
Turnover $2,463,536 |
Volume 565,229 |
| 30 June 2023 at 4:10pm | ||||
|
Market Cap (13-Nov) $277,610,112 (439th) |
Close (30-Jun) $4.40 |
Volume (30-Jun) 565,229 |
Shortsold (6-Nov) 1,890,557 (2.31%) (155th) |
|
52w High $6.04 |
52w Low $2.04 |
P/E 263.16 |
EPS 0.31 |
NEXTSTELLIS FDA exclusivity & phase III data published
MYX released this announcement to the ASX on 27 May 2021, 8:47. The announcement is not marked as price sensitive, and is 3 page(s) in length and 223.51kb in size.
You can view all announcements from MYX and see how they appear on a price chart on the announcements page.
At the date of this announcement, MYX was 1.260% short sold according to ASIC data. It was ranked the 162nd most shorted stock on the ASX. It is now ranked as the 155th most shorted stock on the ASX with 2.309% of total shares short sold as of the latest reported data (06 November 2026).
| Other Recent Announcements from MYX | |
|---|---|
| Notification of cessation of securities - MYX | 30 June 2023, 16:11 |
| Update - Notification of buy-back - MYX | 30 June 2023, 8:19 |
| Update - Notification of buy-back - MYX | 29 June 2023, 8:20 |
| NEXTSTELLIS FDA exclusivity & phase III data published | 27 May 2021, 8:47 |
| Becoming a substantial holder | 14 May 2021, 16:09 |
| Appendix 2A and Notice under ASX Listing Rule 3.10A | 13 May 2021, 16:40 |
| Change in substantial holding | 20 April 2021, 17:41 |
If you were already registered, log in here.